Article
Oncology
Difei Lu, Jun Yao, Geheng Yuan, Ying Gao, Junqing Zhang, Xiaohui Guo
Summary: This article investigates the prevalence and demographic characteristics of immune checkpoint inhibitor (ICI)-related thyroid dysfunction (ICI-TD) and explores the risk factors of poor clinical outcomes. It finds that thyroid dysfunction is common in ICI treatment, especially in combination therapy.
Review
Oncology
Qian Sun, Hongyan Sun, Nan Wu, Yue Hu, Fangqing Zhang, Xianling Cong
Summary: This study found that among patients with melanoma treated with immune checkpoint inhibitors, the development of non-thyroid endocrine irAEs and cutaneous irAEs is associated with better prognosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Liu Li, Kuang Tianrui, Li Chunlei, Qiu Zhendong, Chen Xiaoyan, Deng Wenhong
Summary: The presence of HYDIN mutations in melanoma patients may serve as a potential predictive biomarker for the efficacy of immune checkpoint inhibitors (ICIs) treatment.
Article
Oncology
Meghana Kesireddy, Alissa Marr, Makayla Schissel, Apar K. Ganti
Summary: This retrospective study evaluated the effects of immune checkpoint inhibitors (ICIs) in patients with preexisting organ dysfunction. The results showed that ICIs were well tolerated in patients with chronic kidney disease (CKD), cirrhosis, chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF), with no significant differences in outcomes observed between patients with and without immune-related adverse events (IrAEs).
Article
Oncology
Anngela C. Adams, Elizabeth S. Borden, Anne M. Macy, Nick Thomson, Haiyan Cui, Mark Gimbel, Melissa A. Wilson, Kenneth H. Buetow, Denise J. Roe, David J. DiCaudo, Jade Homsi, Karen Taraszka Hastings
Summary: This study found that high expression of GILT mRNA in tumor samples and GILT protein in melanoma cells is associated with improved survival in patients treated with immune checkpoint inhibitors (ICI). These findings suggest that GILT may serve as a biomarker to predict the response to ICI in patients with metastatic melanoma.
Article
Immunology
Lilong Zhang, Chen Chen, Dongqi Chai, Chunlei Li, Yongjun Guan, Li Liu, Tianrui Kuang, Wenhong Deng, Weixing Wang
Summary: This meta-analysis aimed to evaluate the influence of antibiotic use on the survival of hepatocellular carcinoma patients treated with immune checkpoint inhibitors. The results showed that antibiotic use did not affect the overall survival, progression-free survival, objective response rate, and disease control rate in these patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Lu-shan Xiao, Rui-ning Li, Hao Cui, Chang Hong, Chao-yi Huang, Qi-mei Li, Cheng-yi Hu, Zhong-yi Dong, Hong-bo Zhu, Li Liu
Summary: This study explored the association between sarcopenia and CT-derived fat content with the prognosis of primary liver cancer patients treated with immune checkpoint inhibitors (ICIs). The results showed that sarcopenia and low fat tissue content were significantly associated with poor clinical outcomes.
Article
Oncology
Simone M. Goldinger, Kristina Buder-Bakhaya, Serigne N. Lo, Andrea Forschner, Meredith McKean, Lisa Zimmer, Chloe Khoo, Reinhard Dummer, Zeynep Eroglu, Elizabeth I. Buchbinder, Paolo A. Ascierto, Ralf Gutzmer, Elisa A. Rozeman, Christoph Hoeller, Douglas B. Johnson, Anja Gesierich, Peter Koelblinger, Naima Bennannoune, Justine Cohen, Katharina C. Kaehler, Melissa A. Wilson, Jonathan Cebon, Victoria Atkinson, Jessica L. Smith, Olivier Michielin, Georgina Long, Jessica C. Hassel, Benjamin Weide, Lauren E. Haydu, Dirk Schadendorf, Grant McArthur, Patrick A. Ott, Christian Blank, Caroline Robert, Ryan Sullivan, Axel Hauschild, Matteo S. Carlino, Claus Garbe, Michael A. Davies, Alexander M. Menzies
Summary: Chemotherapy has limited activity in patients with metastatic melanoma who have failed checkpoint inhibitor therapy, although the activity varies among different chemotherapy regimens.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Pharmacology & Pharmacy
Xue-lin Zou, Wei-yong Chen, Guang-yan Zhang, Hua Ke, Qiu-hong Yang, Xiao-bo Li
Summary: This article discusses the potential adverse effects of thromboembolism in patients receiving immune checkpoint inhibitors, including high-risk factors, underlying mechanisms, incidence, prognosis, intervention, and treatment measures.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Raquel Romao, Ana S. S. Mendes, Ridhi Ranchor, Maria Joao Ramos, Joao Coelho, Rita Carrilho Pichel, Sergio Xavier Azevedo, Paula Fidalgo, Antonio Araujo
Summary: The use of immune checkpoint inhibitors (ICI) presents a new challenge for oncologists, namely immune-related adverse events (irAE). The correlation between irAE onset and ICI efficacy is still unclear. This study provides further evidence to support this association and highlights the need for additional research in this area.
Article
Oncology
Suzan H. Stuermer, Axel Lechner, Carola Berking
Summary: In high-risk melanoma patients treated with immune checkpoint inhibitors, a high percentage experience immune-related adverse events, with some cases classified as severe or life-threatening. Common symptoms include diarrhea, fatigue, hypothyroidism, and hepatitis. Rare cases may involve otovestibular dysfunction and uveitis, with unclear pathogenic mechanisms.
JOURNAL OF IMMUNOTHERAPY
(2021)
Article
Oncology
Yutian Si, Anqi Lin, Weimin Ding, Hui Meng, Peng Luo, Jian Zhang
Summary: The study found that the CARD11 mutation is associated with longer overall survival and better prognosis after ICI treatment, higher immunogenicity, and significantly downregulated expression of genes related to immunosuppression. Tumors with CARD11 mutation showed significantly downregulated pathways related to immunosuppression and upregulated pathways related to immune activation. Additionally, CARD11-mutant tumors had more mutations in the DNA damage response and repair (DDR) pathway.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Oncology
Jessica J. J. Waninger, Leslie A. A. Fecher, Christopher Lao, Sarah Yentz, Michael D. D. Green, Hakan Demirci
Summary: Uveal melanoma is a rare but common eye tumor with no standardized treatment for metastatic disease. This study suggests that lactate dehydrogenase and white blood cell ratio could be useful blood markers for determining treatment response.
Article
Biochemistry & Molecular Biology
Yi Li, Yue Zang, Tianda Fan, Zhaochen Li, Anzi Li, Wei Lv, Qingqing Wang, Qinglan Li, Yuanyuan Li, Quan Li, Zhongsheng Sun, Huajing Teng
Summary: This study reveals shared molecular signatures underlying thyroid dysfunction between patients receiving anti-PD-1/PD-L1 inhibitors and PTC patients suffering from Hashimoto thyroiditis, which may provide insights into managing adverse events during cancer immunotherapy.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Article
Oncology
Toru Kadono, Satoru Iwasa, Kengo Nagashima, Kotoe Oshima, Shun Yamamoto, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Toshikazu Ushijima, Narikazu Boku
Summary: The clinical efficacy of immune checkpoint inhibitors (ICIs) against gastric cancer varies depending on the metastatic site and progression pattern. This retrospective study investigated the response to nivolumab and clinical outcomes based on metastatic site and progression pattern in patients with advanced gastric cancer.